Irina M. Onofriychuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irina M. Onofriychuk has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Azizzhon D. Zikiryachodzhaev
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
17 shared publications - E. K. Saribekyan
P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre
8 shared publications - Elena A. Rasskazova
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation
5 shared publications - Maria Yu. Vlasova
National Medical Research Radiology Centre
5 shared publications - Shakhnoz G. Khakimova
N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
5 shared publications - Stanislav Mikhailov
P.A. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre
5 shared publications
Latest Publications
- 20 February 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (1)
Sentinel lymph node biopsy in breast carcinoma in situ
Due to the rapid development of breast cancer screening and its detection more often in earlier stages, preinvasive forms of breast cancer account for up to 20% of all forms of malignant neoplasms of the breast. Therefore, today in the treatment of breast cancer with ductal carcinoma in situ (DCIS) there is a tendency to de-escalate surgical intervention. This article reviews the literature, as well as current domestic and international clinical guidelines for the treatment of DCIS in order to study the frequency of detection of metastatic lesions during sentinel lymph node examination (SLNB), and assesses the feasibility and indications for SLNB. The findings of the current review article can supplement the existing data on the indications for SLNB in patients with DCIS and help clarify the recommendations for the treatment of ductal carcinoma in situ (DCIS).
- 20 February 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (1)
Sentinel lymph node biopsy in breast carcinoma in situ
Due to the rapid development of breast cancer screening and its detection more often in earlier stages, preinvasive forms of breast cancer account for up to 20% of all forms of malignant neoplasms of the breast. Therefore, today in the treatment of breast cancer with ductal carcinoma in situ (DCIS) there is a tendency to de-escalate surgical intervention. This article reviews the literature, as well as current domestic and international clinical guidelines for the treatment of DCIS in order to study the frequency of detection of metastatic lesions during sentinel lymph node examination (SLNB), and assesses the feasibility and indications for SLNB. The findings of the current review article can supplement the existing data on the indications for SLNB in patients with DCIS and help clarify the recommendations for the treatment of ductal carcinoma in situ (DCIS).
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 46-58
Fertility preservation in women with BRCA1/2‑related cancers: contemporary strategies, international recommendations, and a multidisciplinary approach
Inherited mutations in the BRCA1/BRCA2 genes significantly increase the risk of breast and ovarian cancer in women of reproductive age, posing a clinical and socioeconomic challenge due to loss of fertility during cancer treatment and preventive interventions. The expansion of genetic testing programs is shifting the focus to proactive management of reproductive potential, requiring the integration of oncology, reproductive medicine, and medical genetics. The novelty of this review lies in its comprehensive synthesis of data on the impact of treatment and prevention of BRCA-associated cancer on fertility and a critical assessment of the effectiveness of fertility preservation strategies. Purpose of the study . To summarize and analyze current advances, clinical guidelines, and unresolved issues related to preserving reproductive function in women carrying BRCA1/BRCA2 mutations. Materials and methods . A systematic search of PubMed/MEDLINE, Embase, the Cochrane Library, and Web of Science was performed, along with an analysis of international guidelines (ESHRE (European Society of Human Reproduction and Embryology), ASCO (American Society of Clinical Oncology), ASRM (American Society for Reproductive Medicine), NCCN (National Comprehensive Cancer Network), ESMO (European Society for Medical Oncology)). Keywords: “BRCA1,” “BRCA2,” “fertility preservation,” “oocyte cryopreservation,” “embryo cryopreservation,” “ovarian tissue cryopreservation,” “PGT-M,” “PARP inhibitors,” and “chemotherapy gonadotoxicity.”, in the period of 2005–2025. Studies with incomplete data, duplicates, reviews of low methodological quality, and case series with fewer than 10 observations were excluded. Priority was given to meta-analyses, RCTs, large cohorts, and consensus reports. Results. The included studies included cancer patients before and after treatment, BRCA carriers with and without prophylactic strategies, and IVF/ICSI cohorts with cryopreservation. Alkylating agents and taxanes have been shown to increase the risk of premature ovarian failure, while GnRH agonists partially reduce the risk of ovarian toxicity. The efficacy of oocyte and embryo cryopreservation in BRCA-positive women is comparable to the population-based efficacy with optimized stimulation (GnRH antagonists, letrozole-containing protocols). Ovarian tissue cryopreservation is applicable in urgently needed patients but requires oncoprotective assessment. PGT-M ensures the selection of mutation-free embryos. Multidisciplinary pathways improve the timelines of referrals and the completion rate of fertility preservation programs Conclusion. Early identification of BRCA-positive women and the integration of a gynecologic oncologist, reproductive specialist, and geneticist enable personalized strategy selection: gamete/embryo cryopreservation, ovarian tissue, pharmacoprotection, and PGT-M. Standardized stimulation protocols and therapy timing, long-term safety and fertility data, and economic access models are needed. Improvements in biotechnology and patient pathways improve reproductive outcomes and quality of life.
- 17 December 2025
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 46-58
Fertility preservation in women with BRCA1/2‑related cancers: contemporary strategies, international recommendations, and a multidisciplinary approach
Inherited mutations in the BRCA1/BRCA2 genes significantly increase the risk of breast and ovarian cancer in women of reproductive age, posing a clinical and socioeconomic challenge due to loss of fertility during cancer treatment and preventive interventions. The expansion of genetic testing programs is shifting the focus to proactive management of reproductive potential, requiring the integration of oncology, reproductive medicine, and medical genetics. The novelty of this review lies in its comprehensive synthesis of data on the impact of treatment and prevention of BRCA-associated cancer on fertility and a critical assessment of the effectiveness of fertility preservation strategies. Purpose of the study . To summarize and analyze current advances, clinical guidelines, and unresolved issues related to preserving reproductive function in women carrying BRCA1/BRCA2 mutations. Materials and methods . A systematic search of PubMed/MEDLINE, Embase, the Cochrane Library, and Web of Science was performed, along with an analysis of international guidelines (ESHRE (European Society of Human Reproduction and Embryology), ASCO (American Society of Clinical Oncology), ASRM (American Society for Reproductive Medicine), NCCN (National Comprehensive Cancer Network), ESMO (European Society for Medical Oncology)). Keywords: “BRCA1,” “BRCA2,” “fertility preservation,” “oocyte cryopreservation,” “embryo cryopreservation,” “ovarian tissue cryopreservation,” “PGT-M,” “PARP inhibitors,” and “chemotherapy gonadotoxicity.”, in the period of 2005–2025. Studies with incomplete data, duplicates, reviews of low methodological quality, and case series with fewer than 10 observations were excluded. Priority was given to meta-analyses, RCTs, large cohorts, and consensus reports. Results. The included studies included cancer patients before and after treatment, BRCA carriers with and without prophylactic strategies, and IVF/ICSI cohorts with cryopreservation. Alkylating agents and taxanes have been shown to increase the risk of premature ovarian failure, while GnRH agonists partially reduce the risk of ovarian toxicity. The efficacy of oocyte and embryo cryopreservation in BRCA-positive women is comparable to the population-based efficacy with optimized stimulation (GnRH antagonists, letrozole-containing protocols). Ovarian tissue cryopreservation is applicable in urgently needed patients but requires oncoprotective assessment. PGT-M ensures the selection of mutation-free embryos. Multidisciplinary pathways improve the timelines of referrals and the completion rate of fertility preservation programs Conclusion. Early identification of BRCA-positive women and the integration of a gynecologic oncologist, reproductive specialist, and geneticist enable personalized strategy selection: gamete/embryo cryopreservation, ovarian tissue, pharmacoprotection, and PGT-M. Standardized stimulation protocols and therapy timing, long-term safety and fertility data, and economic access models are needed. Improvements in biotechnology and patient pathways improve reproductive outcomes and quality of life.
- Open Access
- 17 September 2025
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 15 (3) , 244-250
Clinical Characteristics and Features of Noninvasive Breast Cancer
Introduction. This article presents the study of 110 female patients diagnosed with stage 0 breast cancer conducted at the P. Hertsen Moscow Oncology Research Institute between 2023 and 2024. Materials and methods. By histological type, ductal carcinoma in situ (Tis, DCIS) predominated in 100/110 cases (90.9%), followed by Paget’s disease (Tis, Paget) in 7/110 (6.4%), and lobular carcinoma in situ (Tis, LCIS) in 3/110 (2.7%). Mastectomy was performed in 17 patients (15.5%), skin-sparing mastectomy with reconstruction in 44 (40%), and breast-conserving surgery in 49 (44.5%). Results. According to routine histological examination, progression of DCIS was identified in 42/110 patients (38.2%). Among them, stage I breast cancer was diagnosed in 33.6% and stage II in 4.5%. In routine morphological examination, positive resection margins (R1) were detected in 15 patients (13.6%). Discussion. Breast MRI in non-invasive breast cancer is an essential procedure for determining disease extent, assessing multifocality or multicentricity, and thus guiding the decision on breast-conserving surgery versus mastectomy. Another important issue is the need to evaluate sentinel lymph nodes in cases of non-invasive breast cancer. Conclusion. Local recurrences of breast cancer in the analyzed group were diagnosed in 2 patients (1.8 ± 1.6%). Progression of stage 0 breast cancer to higher stages, i.e., cTis → pT+, was observed in 42/110 patients (38.2%). Despite the extent of disease (mean size of carcinoma in situ was 42 mm), breastconserving surgery or nipple-/skin-sparing mastectomy with reconstruction were performed in 93% of cases. Thus, carcinoma in situ may progress to higher stages in about 40% of patients. The role of diagnostic methods in assessing breast cancer stage is therefore crucial for selecting an optimal surgical management.
- 17 September 2025
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 15 (3) , 244-250
Open AccessClinical Characteristics and Features of Noninvasive Breast Cancer
Introduction. This article presents the study of 110 female patients diagnosed with stage 0 breast cancer conducted at the P. Hertsen Moscow Oncology Research Institute between 2023 and 2024. Materials and methods. By histological type, ductal carcinoma in situ (Tis, DCIS) predominated in 100/110 cases (90.9%), followed by Paget’s disease (Tis, Paget) in 7/110 (6.4%), and lobular carcinoma in situ (Tis, LCIS) in 3/110 (2.7%). Mastectomy was performed in 17 patients (15.5%), skin-sparing mastectomy with reconstruction in 44 (40%), and breast-conserving surgery in 49 (44.5%). Results. According to routine histological examination, progression of DCIS was identified in 42/110 patients (38.2%). Among them, stage I breast cancer was diagnosed in 33.6% and stage II in 4.5%. In routine morphological examination, positive resection margins (R1) were detected in 15 patients (13.6%). Discussion. Breast MRI in non-invasive breast cancer is an essential procedure for determining disease extent, assessing multifocality or multicentricity, and thus guiding the decision on breast-conserving surgery versus mastectomy. Another important issue is the need to evaluate sentinel lymph nodes in cases of non-invasive breast cancer. Conclusion. Local recurrences of breast cancer in the analyzed group were diagnosed in 2 patients (1.8 ± 1.6%). Progression of stage 0 breast cancer to higher stages, i.e., cTis → pT+, was observed in 42/110 patients (38.2%). Despite the extent of disease (mean size of carcinoma in situ was 42 mm), breastconserving surgery or nipple-/skin-sparing mastectomy with reconstruction were performed in 93% of cases. Thus, carcinoma in situ may progress to higher stages in about 40% of patients. The role of diagnostic methods in assessing breast cancer stage is therefore crucial for selecting an optimal surgical management.
- Open Access
- 29 June 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (2) , 103-112
Rare Disease: Breast Desmoid-Type Fibromatosis.
The article presents a rare form of pathological neoplasms — breast desmoid type fibromatosis. There are etiology and pathogenesis of the disease, clinical and morphological features, diagnostics and tactics of treatment of the disease. Widely covered clinical examples from the practice of a surgeon-oncologist. Desmoid fibromatosis (DF) is an aggressive non-metastatic mesenchymal formation that arises from musculoponeurotic structures. DF accounts for 0.03 % to 0.1 % of solid tumors and 3 % of mesenchymal tumors. Among breast pathology, this neoplasm is even rarer (0.2 %). Due to the rarity of such pathology, clinicians are not always able to correctly interpret the diagnostic picture and recognize the disease. The etiology and pathogenesis of the disease are also not fully understood, and therefore there are no standards for the treatment of desmoid fibromatosis. Surgical treatment remains the main one. To reduce the frequency of recurrence of the disease, the surgeon needs to achieve clean edges of the resection. Radiation therapy, hormone therapy, targeted therapy, and chemotherapy may additionally be considered as an alternative type of treatment. When the clean edges of the resection are reached, strict dynamic monitoring of pa is considered as further treatment.
- 29 June 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (2) , 103-112
Open AccessRare Disease: Breast Desmoid-Type Fibromatosis.
The article presents a rare form of pathological neoplasms — breast desmoid type fibromatosis. There are etiology and pathogenesis of the disease, clinical and morphological features, diagnostics and tactics of treatment of the disease. Widely covered clinical examples from the practice of a surgeon-oncologist. Desmoid fibromatosis (DF) is an aggressive non-metastatic mesenchymal formation that arises from musculoponeurotic structures. DF accounts for 0.03 % to 0.1 % of solid tumors and 3 % of mesenchymal tumors. Among breast pathology, this neoplasm is even rarer (0.2 %). Due to the rarity of such pathology, clinicians are not always able to correctly interpret the diagnostic picture and recognize the disease. The etiology and pathogenesis of the disease are also not fully understood, and therefore there are no standards for the treatment of desmoid fibromatosis. Surgical treatment remains the main one. To reduce the frequency of recurrence of the disease, the surgeon needs to achieve clean edges of the resection. Radiation therapy, hormone therapy, targeted therapy, and chemotherapy may additionally be considered as an alternative type of treatment. When the clean edges of the resection are reached, strict dynamic monitoring of pa is considered as further treatment.
- Open Access
- 4 March 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (1) , 8-25
Results of targeted lymphadenectomy in patients with breast cancer cT1-3N1M0 after neoadjuvant systemic therapy
Purpose of the study. To evaluate the results of targeted lymphadenectomy (TLAE) in patients with breast cancer (BC) cT1–3N1M0 after neoadjuvant systemic therapy (NAST). Patients and methods. The study represents a prospective analysis of 83 patients diagnosed with breast cancer in stage T1–3N1M0 who were treated in the Department of Reconstructive and Plastic Surgery of the breast and skin at the P. Hertsen Moscow Oncology Research Institute (Moscow, Russian Federation). The patients were divided into two groups: in the main group 1 (n = 45), TLAE was performed using a metal tag (clip) after surgery; in the control group 2 (n = 38), classical lymphadenectomy (LAE) was performed. The following characteristics were evaluated: the size of the primary tumor and its localization, the degree of malignan cy (G), the biological subtype of the tumor, the number of sentinel lymph nodes (SLN), the number of metastases in SLN, damage to other lymph nodes, the number of patients who moved from cN1 to cN0. According to these characteristics, the two groups were comparable and there were no statistically significant differences. The effectiveness of NAST was assessed by the frequency of complete pathomorphological regression of the lesion of the studied tissue. The frequency of identification of sentinel lymph nodes was assessed with urgent cytological and routine pathomorphological studies. Results. In group 1, a complete pathomorphological response in the mammary gland was 37.8 %, in group 2 – 31.6 %. A complete pathomorphological response in the affected lymph node (N0) after neoadjuvant polychemotherapy (NAST) was achieved in 51.1 % of patients in group 1 and 52.6 % in group 2. The frequency of identification of sentinel lymph nodes during biopsy in both groups was 100 %. The frequency of identification of the installed tag was 100 %. The frequency of coincidences of the clipped lymph node with the sentinel lymph node was 65 %. In one case, migration of the installed label was noted. The efficiency of using the navigation explorer was 93 %. Conclusion. The results obtained confirm the expediency, feasibility and high efficiency of de-escalation of surgical intervention in the form of TLAE. Our study also demonstrates the relative simplicity and accuracy of using a metal tag to achieve TLAE goals.
- 4 March 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (1) , 8-25
Open AccessResults of targeted lymphadenectomy in patients with breast cancer cT1-3N1M0 after neoadjuvant systemic therapy
Purpose of the study. To evaluate the results of targeted lymphadenectomy (TLAE) in patients with breast cancer (BC) cT1–3N1M0 after neoadjuvant systemic therapy (NAST). Patients and methods. The study represents a prospective analysis of 83 patients diagnosed with breast cancer in stage T1–3N1M0 who were treated in the Department of Reconstructive and Plastic Surgery of the breast and skin at the P. Hertsen Moscow Oncology Research Institute (Moscow, Russian Federation). The patients were divided into two groups: in the main group 1 (n = 45), TLAE was performed using a metal tag (clip) after surgery; in the control group 2 (n = 38), classical lymphadenectomy (LAE) was performed. The following characteristics were evaluated: the size of the primary tumor and its localization, the degree of malignan cy (G), the biological subtype of the tumor, the number of sentinel lymph nodes (SLN), the number of metastases in SLN, damage to other lymph nodes, the number of patients who moved from cN1 to cN0. According to these characteristics, the two groups were comparable and there were no statistically significant differences. The effectiveness of NAST was assessed by the frequency of complete pathomorphological regression of the lesion of the studied tissue. The frequency of identification of sentinel lymph nodes was assessed with urgent cytological and routine pathomorphological studies. Results. In group 1, a complete pathomorphological response in the mammary gland was 37.8 %, in group 2 – 31.6 %. A complete pathomorphological response in the affected lymph node (N0) after neoadjuvant polychemotherapy (NAST) was achieved in 51.1 % of patients in group 1 and 52.6 % in group 2. The frequency of identification of sentinel lymph nodes during biopsy in both groups was 100 %. The frequency of identification of the installed tag was 100 %. The frequency of coincidences of the clipped lymph node with the sentinel lymph node was 65 %. In one case, migration of the installed label was noted. The efficiency of using the navigation explorer was 93 %. Conclusion. The results obtained confirm the expediency, feasibility and high efficiency of de-escalation of surgical intervention in the form of TLAE. Our study also demonstrates the relative simplicity and accuracy of using a metal tag to achieve TLAE goals.
- 1 January 2025
- Published by Geotar-Media Publishing Group in Clinical and Experimental Surgery. Petrovsky journal
- Vol. 13 (4)
Treatment of patients with breast cancer stage I–II A, B (pT1-2 N0-1) after skin sparing/nipple sparing mastectomies with implant reconstruction after radiation therapy: a randomized trial
- 1 January 2025
- Published by Geotar-Media Publishing Group in Clinical and Experimental Surgery. Petrovsky journal
- Vol. 13 (4)
Treatment of patients with breast cancer stage I–II A, B (pT1-2 N0-1) after skin sparing/nipple sparing mastectomies with implant reconstruction after radiation therapy: a randomized trial
- Open Access
- 31 December 2024
- Published by Pensoft Publishers in Folia Medica
- Vol. 66 (6) , 895-904
Sentinel lymph nodes biopsy for malignant tumors using Technefit radioactive colloid Technetium 99mTc
Introduction: Technetium-99m (99mTc) is a short-lived nanocolloid nuclide widely used by oncologists to diagnose and identify cancer dissemination. Aim: The aim of the current study was to develop the technique of radiopharmaceutical preparation (RPP) of Technefit99mTc aimed at examining sentinel lymph nodes (SLN) before surgery. Materials and methods: We performed a series of trials (33 patients). Based on the information obtained from the portable gamma detector NEO2000 during surgery, a biopsy of the sentinel lymph nodes was carried out when RPP Technefit 99mTc accumulated in a specific lymph node. Results: We determined maximum activities, volume, and peculiarities of administration of radioactive colloid Technefit99mTc in order to examine and perform the biopsy of SLN in the patients with malignant tumors. The most informative results in terms of scintigraphy images of sentinel lymph nodes were revealed in the first trial of the research, with all 5 cases (100%) showing positive results. The first trial included Technefit intradermal-hypodermal injection into one point above the tumor node, RPP activity of 75 to 200 mBq at a room temperature of 21°C, without preliminary anesthesia with Novocain solution. Conclusion: We determined the most efficient dosages of activities, volume, and characteristics of radioactive colloid administration aimed at the examination and biopsy of sentinel lymph nodes using the radiopharmaceutical preparation Technefit 99mTc in patients with malignant tumors of different localizations, namely breast cancer and skin melanoma. In some cases, we did not find any signs of considerable lowering of the Technefit 99mTc activity, which shows that there is a very slow filtration of Technefit 99mTc through the pores of lymph capillaries.
- 31 December 2024
- Published by Pensoft Publishers in Folia Medica
- Vol. 66 (6) , 895-904
Open AccessSentinel lymph nodes biopsy for malignant tumors using Technefit radioactive colloid Technetium 99mTc
Introduction: Technetium-99m (99mTc) is a short-lived nanocolloid nuclide widely used by oncologists to diagnose and identify cancer dissemination. Aim: The aim of the current study was to develop the technique of radiopharmaceutical preparation (RPP) of Technefit99mTc aimed at examining sentinel lymph nodes (SLN) before surgery. Materials and methods: We performed a series of trials (33 patients). Based on the information obtained from the portable gamma detector NEO2000 during surgery, a biopsy of the sentinel lymph nodes was carried out when RPP Technefit 99mTc accumulated in a specific lymph node. Results: We determined maximum activities, volume, and peculiarities of administration of radioactive colloid Technefit99mTc in order to examine and perform the biopsy of SLN in the patients with malignant tumors. The most informative results in terms of scintigraphy images of sentinel lymph nodes were revealed in the first trial of the research, with all 5 cases (100%) showing positive results. The first trial included Technefit intradermal-hypodermal injection into one point above the tumor node, RPP activity of 75 to 200 mBq at a room temperature of 21°C, without preliminary anesthesia with Novocain solution. Conclusion: We determined the most efficient dosages of activities, volume, and characteristics of radioactive colloid administration aimed at the examination and biopsy of sentinel lymph nodes using the radiopharmaceutical preparation Technefit 99mTc in patients with malignant tumors of different localizations, namely breast cancer and skin melanoma. In some cases, we did not find any signs of considerable lowering of the Technefit 99mTc activity, which shows that there is a very slow filtration of Technefit 99mTc through the pores of lymph capillaries.
- Open Access
- 27 July 2024
- Published by Research Institute of Microsurgery in Issues of Reconstructive and Plastic Surgery
- Vol. 27 (2) , 5-18
Oncoplastic resections for breast cancer: the effect of tumor localization and morphological features on the choice of surgical method: history of the issue (Literature review)
The development of surgical technology, advances in a chemotherapy and radiation therapy for the treatment of the breast cancer is a solution of not only medical, but also aesthetic problems. A multidisciplinary approach to the treatment of breast cancer has made it possible to use less aggressive tactics of surgical treatment, complementing the operation with other methods of neoadjuvant and adjuvant therapy.Despite the fact is a modern conditions the issue of rehabilitation and preservation of the quality of life of patients after surgical treatment is more acute than ever, today there are no collecting recommendations for the use of breast conserving treatment methods for breast cancer, it is can be useful to adequately assess the risk of tumor recurrence and it is advisable to determine the scope of surgical treatment. However, the experience accumulated by surgeons allows us to identify risk factors for tumor recurrence depending on the characteristics of its location and morphological structure of the tumor.Considering the possibilities of modern neoadjuvant chemotherapy, even with an unfavorable immunohistochemical type of tumor, we can offer patients the choice of breast conserving treatment. This issue is especially acute among young patients, the proportion of whom is increasing every year. In this connection, we can achieve faster treatment of breast cancer, as well as achieve a good aesthetic result with minimal surgical interventions, without the help of foreign materials (implants or other mesh).
- 27 July 2024
- Published by Research Institute of Microsurgery in Issues of Reconstructive and Plastic Surgery
- Vol. 27 (2) , 5-18
Open AccessOncoplastic resections for breast cancer: the effect of tumor localization and morphological features on the choice of surgical method: history of the issue (Literature review)
The development of surgical technology, advances in a chemotherapy and radiation therapy for the treatment of the breast cancer is a solution of not only medical, but also aesthetic problems. A multidisciplinary approach to the treatment of breast cancer has made it possible to use less aggressive tactics of surgical treatment, complementing the operation with other methods of neoadjuvant and adjuvant therapy.Despite the fact is a modern conditions the issue of rehabilitation and preservation of the quality of life of patients after surgical treatment is more acute than ever, today there are no collecting recommendations for the use of breast conserving treatment methods for breast cancer, it is can be useful to adequately assess the risk of tumor recurrence and it is advisable to determine the scope of surgical treatment. However, the experience accumulated by surgeons allows us to identify risk factors for tumor recurrence depending on the characteristics of its location and morphological structure of the tumor.Considering the possibilities of modern neoadjuvant chemotherapy, even with an unfavorable immunohistochemical type of tumor, we can offer patients the choice of breast conserving treatment. This issue is especially acute among young patients, the proportion of whom is increasing every year. In this connection, we can achieve faster treatment of breast cancer, as well as achieve a good aesthetic result with minimal surgical interventions, without the help of foreign materials (implants or other mesh).
- Open Access
- 11 June 2024
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 79 (2) , 153-157
Еffect of Radiation Therapy on Breast Reconstruction in Breast Cancer Patients
Background. The surgical stage remains the main one in the combined and complex treatment of breast cancer. Radical mastectomy and reconstructive plastic surgery are the main option for surgical treatment of vast majority patients. Radiation therapy can lead to the development of complications after breast reconstruction, and vice versa, the reconstructed mammary gland can cause technical difficulties for the radiologist to properly adjust the required dose of irradiation. Aim — to choose the optimal method of breast reconstruction using various implants, as well as endoprostheses to minimize post-radiation complications and maintain a high level of quality of life for patients after breast cancer treatment. Methods. The retrospective study was conducted in the department of oncology and reconstructive plastic surgery of the breast and skin in the P.A. Herzen Moscow Research Oncology Institute from June 2013 to November 2017. There were performed 132 operations: 111 subcutaneous mastectomy with one-stage reconstruction with an endoprothesis and 21 mastectomy with a one-stage reconstruction with an endoprothesis. The distribution by stages: I — 57, IIA — 39, IIB — 17, IIIA — 13, IIIC 4; 2 cases of breast sarcoma. Prophylactic mastectomy of the contralateral gland was performed in 22 patients, mastopexy in 8, augmentation in 20. Polyurethane implants were applied in 82 cases (62%). Radiation therapy was performed in 47 patients with total dose 45 Gy. Bilateral reconstruction was performed in 22 patients. Results. The mean follow-up period was 28.44 ± 14.66 months (from 6 to 48 months). The most frequent complication in the postoperative period was the development of capsular contracture: seroma — 20 patients, hematoma — 2, edge necrosis — 6, protrusion — 6, infection — 2 patients. The most common capsular contracture by Baker was III degree, n = 18. The average period of development of capsular contracture was 7.6 ± 11.65 months. Conclusion. Despite the greater number of complications during the one-stage reconstruction, the implants remain in advantage in choosing a method of treating breast cancer by both the patient and the surgeon.
- 11 June 2024
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 79 (2) , 153-157
Open AccessЕffect of Radiation Therapy on Breast Reconstruction in Breast Cancer Patients
Background. The surgical stage remains the main one in the combined and complex treatment of breast cancer. Radical mastectomy and reconstructive plastic surgery are the main option for surgical treatment of vast majority patients. Radiation therapy can lead to the development of complications after breast reconstruction, and vice versa, the reconstructed mammary gland can cause technical difficulties for the radiologist to properly adjust the required dose of irradiation. Aim — to choose the optimal method of breast reconstruction using various implants, as well as endoprostheses to minimize post-radiation complications and maintain a high level of quality of life for patients after breast cancer treatment. Methods. The retrospective study was conducted in the department of oncology and reconstructive plastic surgery of the breast and skin in the P.A. Herzen Moscow Research Oncology Institute from June 2013 to November 2017. There were performed 132 operations: 111 subcutaneous mastectomy with one-stage reconstruction with an endoprothesis and 21 mastectomy with a one-stage reconstruction with an endoprothesis. The distribution by stages: I — 57, IIA — 39, IIB — 17, IIIA — 13, IIIC 4; 2 cases of breast sarcoma. Prophylactic mastectomy of the contralateral gland was performed in 22 patients, mastopexy in 8, augmentation in 20. Polyurethane implants were applied in 82 cases (62%). Radiation therapy was performed in 47 patients with total dose 45 Gy. Bilateral reconstruction was performed in 22 patients. Results. The mean follow-up period was 28.44 ± 14.66 months (from 6 to 48 months). The most frequent complication in the postoperative period was the development of capsular contracture: seroma — 20 patients, hematoma — 2, edge necrosis — 6, protrusion — 6, infection — 2 patients. The most common capsular contracture by Baker was III degree, n = 18. The average period of development of capsular contracture was 7.6 ± 11.65 months. Conclusion. Despite the greater number of complications during the one-stage reconstruction, the implants remain in advantage in choosing a method of treating breast cancer by both the patient and the surgeon.
- 17 January 2024
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 18-23
Palliative surgical treatment in patients with breast cancer
Last many years breast cancer on a leading position in the structure of oncological pathology among the female population. Patients with metastatic breast cancer, as well as with the presence of tumors with incipient decay or bleeding, are currently considered as patients for complex palliative systemic treatment. The question of the expediency of performing an operation in such a pathology occurs quite often in the daily practice of an oncologist-surgeon. Of course, such life-threatening conditions as decaying breast tumors, bleeding from them, do not raise doubts about the urgency of providing palliative surgical treatment, which is often it is sanitation mastectomy. However, the need for a surgical stage of treatment in the complex palliative therapy of metastatic breast cancer raises many questions. The possibilities of treating metastatic breast cancer have expanded significantly due to the development of drug therapy regimens, up to treating it as a chronic disease. The success of drug breast cancer treatment gives a chance to prolong the life of patients for many years. Thus, in the process of long-term treatment of these patients, various situations arise that require an individual solution. Based on the results of studies, the authors conclude that the decision to remove the primary breast lesion in such patients should be individualized and based on the opinion of the oncologist-surgeon, chemotherapist and radiation therapist, taking into account the potential risk, as well as the subsequent quality of life. In addition, as it turned out, the surgical stage of treatment in such patients not only improves the subsequent quality of life, but also improves oncological indicators. This article discusses the indications and contraindications for performing palliative surgical treatment of patients with breast cancer, based on world studies and our own experience and a clinical study.
- 17 January 2024
- Published by Alfmed LLC in Medical alphabet
- No. 36,p. 18-23
Palliative surgical treatment in patients with breast cancer
Last many years breast cancer on a leading position in the structure of oncological pathology among the female population. Patients with metastatic breast cancer, as well as with the presence of tumors with incipient decay or bleeding, are currently considered as patients for complex palliative systemic treatment. The question of the expediency of performing an operation in such a pathology occurs quite often in the daily practice of an oncologist-surgeon. Of course, such life-threatening conditions as decaying breast tumors, bleeding from them, do not raise doubts about the urgency of providing palliative surgical treatment, which is often it is sanitation mastectomy. However, the need for a surgical stage of treatment in the complex palliative therapy of metastatic breast cancer raises many questions. The possibilities of treating metastatic breast cancer have expanded significantly due to the development of drug therapy regimens, up to treating it as a chronic disease. The success of drug breast cancer treatment gives a chance to prolong the life of patients for many years. Thus, in the process of long-term treatment of these patients, various situations arise that require an individual solution. Based on the results of studies, the authors conclude that the decision to remove the primary breast lesion in such patients should be individualized and based on the opinion of the oncologist-surgeon, chemotherapist and radiation therapist, taking into account the potential risk, as well as the subsequent quality of life. In addition, as it turned out, the surgical stage of treatment in such patients not only improves the subsequent quality of life, but also improves oncological indicators. This article discusses the indications and contraindications for performing palliative surgical treatment of patients with breast cancer, based on world studies and our own experience and a clinical study.